The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
First-in-human mRNA CAR therapy: Correlative biomarker analysis from the MT-302 phase 1 study targeting TROP2 in patients with advanced epithelial tumors.
 
Charlotte Lemech
Consulting or Advisory Role - Sanofi
Travel, Accommodations, Expenses - Amgen
 
Rasha Cosman
No Relationships to Disclose
 
Timothy Humphries
No Relationships to Disclose
 
Ganessan Kichenadasse
No Relationships to Disclose
 
Gary Richardson
Research Funding - Adagene (Inst); Agenus (Inst); AstraZeneca (Inst); BeiGene (Inst); Bio-Thera Solutions (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb (Inst); CBT Pharmaceuticals (Inst); ChemoCentryx (Inst); Corvus Pharmaceuticals (Inst); Curon Biopharmaceutical (Inst); D3 Bio (Inst); D3 Bio (Wuxi) Co., Ltd. (Inst); Eucure Biopharma (Inst); Five Prime Therapeutics (Inst); Fosun Pharma (Inst); Gene Quantum (Inst); Genfleet Therapeutics (Inst); ImmunGen Inc (Inst); Imugene (Inst); InventisBio (Inst); Janssen Oncology (Inst); Keythera Pharmaceuticals (Inst); LaNova Australia (Inst); Medicenna (Inst); Merck (Inst); Minghui Pharmaceutical (Inst); Neoleukin Therapeutics (Inst); Novotech (Inst); Pfizer (Inst); PharmAbcine (Inst); RemeGen (Inst); Roche/Genentech (Inst); Seagen (Inst); Senz Oncology (Inst); Shanghai Henlius Biotech (Inst); Shanghai Henlius Biotech (Inst); Surface Oncology (Inst); Suzhou Alphamab (Inst); Takeda (Inst); Therapim (Inst); Zentalis (Inst)
 
Adnan Nagrial
Stock and Other Ownership Interests - Bristol-Myers Squibb/Celgene
Consulting or Advisory Role - AstraZeneca; Bristol-Myers Squibb; MSD Oncology
Research Funding - Akeso Biopharma (Inst); Amgen (Inst); AstraZeneca/MedImmune (Inst); Bristol-Myers Squibb (Inst); MSD Oncology (Inst)
 
Christina Teng
Employment - Scientia Clinical Research
 
Jia Liu
Honoraria - MSD; Specialised Therapeutics
Consulting or Advisory Role - Greywolf Therapeutics (Inst); Starpharma (Inst); Taiho Pharmaceutical
Research Funding - Abbvie (Inst); ALX Oncology (Inst); AVEO (Inst); AVEO (Inst); Bayer (Inst); Bristol Ms Squibb (Inst); Bristol-Myers Squibb (Inst); Carina Biotech (Inst); Corvus Pharmaceuticals (Inst); Greywolf Therapeutics (Inst); IDEAYA Biosciences (Inst); ImmVirX (Inst); Innovent Biologics (Inst); Merus (Inst); MSD (Inst); Nested Therapeutics (Inst); Regeneron (Inst); Relay Therapeutics (Inst); Starpharma (Inst)
Travel, Accommodations, Expenses - ImmVirX; Innovent Biologics; MSD; Starpharma
 
Anthony Joshua
Stock and Other Ownership Interests - Pricilium Therapeutics
Consulting or Advisory Role - Astellas Pharma (Inst); AstraZeneca (Inst); Bayer (Inst); Eisai (Inst); Grey Wolf Therapeutics (Inst); IDEAYA Biosciences (Inst); Ipsen (Inst); IQvia (Inst); Janssen Oncology (Inst); Mayne Pharma (Inst); Medison (Inst); Merck Serono (Inst); MSD Oncology (Inst); Novartis (Inst); Pfizer (Inst); Sanofi (Inst); Starpharma (Inst)
Research Funding - AstraZeneca (Inst); Bayer (Inst); BeiGene (Inst); Bristol-Myers Squibb (Inst); Corvus Pharmaceuticals (Inst); Genentech (Inst); Immunocore (Inst); Janssen Oncology (Inst); Lilly (Inst); Lilly (Inst); Mayne Pharma (Inst); Merck Sharp & Dohme (Inst); Myeloid Therapeutics (Inst); Pfizer (Inst); Roche/Genentech (Inst)
Patents, Royalties, Other Intellectual Property - Cancer therapeutic methods; Use of Darovasertib for Neoadjuvant treatment ocular Melanoma
 
Heather Cohen
Employment - Bicycle Therapeutics; Myeloid Therapeutics
Stock and Other Ownership Interests - Bicycle Therapeutics
Patents, Royalties, Other Intellectual Property - Bicycle Therapeutics
 
Jeremy Mo
Honoraria - AstraZeneca
Travel, Accommodations, Expenses - Novartis
 
Kate Harvey
No Relationships to Disclose
 
Hanyun Zhang
Stock and Other Ownership Interests - UK patent GB 2106397.9
 
Zheng Ling
Consulting or Advisory Role - Myeloid Therapeutics
Research Funding - Myeloid Therapeutics
 
Nicholas King
Leadership - Myeloid Therapeutics
Stock and Other Ownership Interests - Cour Parmaceutical Development Inc.; Myeloid Therapeutics; OnCour Inc
Research Funding - Myeloid Therapeutics
Patents, Royalties, Other Intellectual Property - Cour Pharmaceutical Development Inc.; OnCour Inc
 
Miriam Barnett
No Relationships to Disclose
 
Michele Cioffi
Employment - Myeloid Therapeutics
Travel, Accommodations, Expenses - Myeloid Therapeutics
 
Matthew Maurer
Employment - IDEAYA Biosciences; Myeloid Therapeutics
Leadership - Myeloid Therapeutics
Stock and Other Ownership Interests - Bristol-Myers Squibb; IDEAYA Biosciences; Myeloid Therapeutics
Consulting or Advisory Role - Jaymes Holland
 
Daniel Getts
Employment - Myeloid Therapeutics
Leadership - Myeloid Therapeutics
Stock and Other Ownership Interests - Myeloid Therapeutics
Patents, Royalties, Other Intellectual Property - Adaptimmune; Cour Pharmaceuticals; Myeloid Therapeutics
 
Alexander Swarbrick
Honoraria - Myeloid Therapeutics; Phenomic AI
Research Funding - Myeloid Therapeutics
Patents, Royalties, Other Intellectual Property - Garvan Institute (Inst)